Why Are a2 Milk Shares Down on Double Digit Revenue Growth?

The a2 Milk Company’s shares (ASX:A2M) were a notable decliner in yesterday’s session, down 4.41% despite delivering preliminary FY26 revenue growth of more than 12%. So what was it under the hood of the headline number that drew market focus?

Headline group revenue of approximately $1.97 billion for FY26, growth of over 12% on the prior year sounds strong when taken alone, yet The a2 Milk share price fell 4.41% to A$7.37, extending the stock’s year-to-date losses to 19.7%. The sell-off follows a sharp 48% rally over the month leading into the update, suggesting markets had front run the print, and set their sights higher.

The stock’s reaction highlights ongoing sensitivity to execution risk in the company’s critical China business, even as broader group metrics appeared solid. Let’s take a closer look.

Financials Masking Key Line

The a2 Milk Company’s preliminary FY26 results revealed a mixed performance across its portfolio. Group revenue reached approximately $1.97 billion, up more than 12% year-over-year, supported by strong sales in English label infant milk formula and liquid milk categories. However, the headline growth masked a concerning 14% decline in China label IMF sales compared to FY25, driven by significant supply chain disruptions during the fourth quarter.

The company’s EBITDA margin came in at the high end of its revised guidance range of 14.0% to 14.5%, down from an earlier target of 15.5% to 16.0% that was cut in April when the supply chain issues first emerged. Net profit after tax is anticipated to be slightly up on FY25, with underlying NPAT also rising, though the margin compression reflected higher logistics costs including air freight expenses and one-off costs to navigate shipping constraints.

Cash conversion proved a bright spot, reaching approximately 70% and well above the company’s previous 50% outlook. This improvement signals better working capital management despite the operational challenges that marked the final quarter of the financial year.

Supply Chain Disruptions

The company faced a compounding set of supply chain disruptions during the fourth quarter of FY26 that materially impacted its China label IMF business. These challenges included freight issues linked to geopolitical tensions affecting key shipping routes through the Middle East, production bottlenecks at manufacturing facilities, and new customs requirements imposed by Chinese authorities. The combination resulted in temporary product shortages on shelves in China during April and May, forcing many customers to switch to competing brands during the stockout period.

Management has indicated that these supply issues have now been largely resolved, with inventory levels back in line with normal operating parameters and increased product flows restored across major distribution channels. The company is now prioritising marketing investments and sales efforts aimed at winning back customers who switched brands during the shortage period, while also accelerating new user acquisition through retail and distribution partnerships.

The supply chain challenges were not entirely unexpected by close observers of the company. a2 Milk had downgraded its FY26 guidance in April, warning that the disruptions would push some revenue and cash collection into FY27 and materially impact China label IMF availability. The preliminary results essentially delivered on that lowered guidance rather than exceeding it, leaving little room for positive surprise after the stock’s substantial pre-announcement rally.

The China Shadow

The decline in China label IMF sales represents a setback for what has historically been a2 Milk’s highest-margin and most strategically important product category. The company has been targeting approximately $2 billion in annual sales and continued market share gains in China’s competitive infant formula market, underpinned by its unique a2 protein positioning and investments in integrated manufacturing capabilities including the Pokeno facility and Yashili NZ acquisition.

The growth strategy has also emphasised diversification beyond China label IMF into English label products, other nutritionals, seniors nutrition, kids UHT milk and expansion in the United States market. This diversification was evident in the FY26 results, with strong performance in categories outside China label IMF helping to offset the decline in that core segment. However, these alternative categories generally carry different margin profiles and competitive dynamics compared to premium China label IMF, raising questions about the sustainability of historical margin levels as the business mix evolves.

The company’s China challenges extend beyond temporary supply disruptions.

Structural headwinds in the market include a declining birth rate that has compressed category volume growth for several years, intensifying competition from well-supported domestic Chinese brands, and evolving regulatory requirements that can create barriers for foreign players. These factors contribute to market caution about assigning premium valuations to companies with heavy China IMF exposure, even when underlying brand equity remains strong.

Street View

Price Targets

Several brokers had flagged valuation concerns heading into the result after the sharp pre-announcement rally pushed the stock back toward long-run average forward multiples. The preliminary numbers, while solid in absolute terms, did not provide the catalyst needed to justify further re-rating in the absence of a confident FY27 outlook that demonstrates margin recovery and China market share recapture.

The company has scheduled its audited FY26 results and FY27 outlook for release on 17 August 2026, which will be the critical next test for market confidence. Management has indicated that efforts will continue to recover China label market share while accelerating new user acquisition, supported by what it describes as now-stable supply chains.

The A2M share price action underscores the challenge facing a2 Milk holders. That is that markets are no longer willing to look past China execution issues, even when the broader business performs well, and the path back to premium valuations will require sustained proof that supply chain vulnerabilities have been addressed and that lost market share can be recaptured in a structurally challenging category.